DEPARTMENT OF HEALTH SERVICES

Division of Medicaid Services F-00081 (07/2020)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR OPIOID DEPENDENCY AGENTS – BUPRENORPHINE

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Opioid Dependency Agents – Buprenorphine Instructions, F-00081A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/
ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed PA/PDL for Opioid Dependency Agents – Buprenorphine form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION				
Name – Member (Last, First, Middle Initial)				
2. Member ID Number	3. Date of Birth – Member			
SECTION II – PRESCRIPTION INFORMATION				
4. Drug Name	5. Drug Strength			
Date Prescription Written	7. Refills			
8. Directions for Use				
9. Name – Prescriber	10. National Provider Identifier – Prescriber			
11. Address – Prescriber (Street, City, State, Zip+4 Code)				
12. Phone Number – Prescriber				
SECTION III – CLINICAL INFORMATION (Required for all PA requests.)				
13. Diagnosis Code and Description				
14. Is the member 16 years of age or older?	☐ Yes ☐ No			
15. Does the prescriber have a valid Drug Addiction Treatment Act of 2000 waiver				
allowing them to prescribe buprenorphine-based agents for opioid dependency				
treatment?	☐ Yes ☐ No			
If yes, enter the prescriber's "X" Drug Enforcement Administration number in the space provided.				



18. Provide detailed clinical justification for prescribing a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv, including clinical information why the member cannot use buprenorphine-naloxone tablets, Suboxone film, and Zubsolv, and why it is medically necessary that the member receive a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv.

SECTION V – AUTHORIZED SIGNATURE

19. SIGNATURE – Prescriber

20. Date Signed

SECTION VI – FOR PHARMACY PROVIDERS USING STAT-PA

21. National Drug Code (11 Digits)

22. Days' Supply Requested (Up to 183 Days)

23. National Provider Identifier

24. Date of Service (mm/dd/ccyy) (For STAT-PA requests, the date of service may be up to 31 days in the future or up

to 14 days in the past.)

PA/PDL for Opioid Dependency Agents – Buprenorphine F-00081 (07/2020)			
25 Place of Service			

Page	3	of	3
------	---	----	---

25. Place of Service				
26. Assigned PA Number				
27. Grant Date	28. Expiration Date	29. Number of Days Approved		

SECTION VII - ADDITIONAL INFORMATION

30. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.